TuHURA Biosciences Receives FDA "Study May Proceed" Notice and IND Clearance for the Evaluation of its TBS-2025 VISTA-Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood-Related Cancers

Phase 1approvedTBS-2025Positive

AI Analysis

Summary

TuHURA Biosciences received FDA 'Study May Proceed' notice and IND clearance for TBS-2025, a VISTA-inhibiting antibody being evaluated in molecularly defined subsets of AML and other blood-related cancers. This clearance enables the company to initiate clinical evaluation of its novel immuno-oncology therapeutic.

Clinical Trial Data

Phase

Phase 1

Outcome Details

FDA issued 'Study May Proceed' notice and IND clearance

Importance:7/10

Sentiment:

0.80

IND clearanceFDA approvalimmuno-oncologyVISTA inhibitorAMLblood cancers

Related Companies

$HURA

Read the original article

Published by PR Newswire Clinical Trials on September 14, 2026 11:45 AM

Read Original